• 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 四川破获一起盗用“老板”微信骗财务转账案 2019-03-29
  • 七一党课:严书翰教授谈重温“不忘初心” 2019-03-26
  • [大笑]山不在高,有仙则名,水不在深,有龙则灵,文不在多,逻辑通透则行! 2019-03-10
  • 青岛国际啤酒节7月开幕 青岛西海岸邀客把酒狂欢--旅游频道 2019-03-10
  • 第一金融网主办
    »您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

    Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis

    2019/5/8 14:50:40  文章来源:文传商讯  作者:文传商讯
    文章简介: Patientsacrossallagesubgroupstreatedwithozanimodlostlesscorticalgreymattervolumethandidthosetreatedwithinterferonbeta-1aover24months Da

    电子游戏 www.hpqjf.com Patients across all age subgroups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon beta-1a over 24 months

    Data from new analysis of pivotal ozanimod trial will be presented at 2019 AAN Annual Meeting

    SUMMIT, N.J. -- (BUSINESS WIRE) --

    Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex® (interferon beta-1a), in adults with relapsing multiple sclerosis (RMS) across all age groups, including patients ages 18 to 25. The analysis will be presented at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019.

    “Brain volume loss is associated with long-term physical disability and cognitive issues in multiple sclerosis,” said Bruce Cree, M.D., Ph.D., M.A.S., Professor of Neurology at the University of California San Francisco (UCSF) Weill Institute for Neurosciences, Clinical Research Director at the UCSF MS Center, and an author of the analysis. “Ozanimod reduced the loss of cortical grey matter volume across all age groups in this study.”

    RADIANCE evaluated two doses of oral ozanimod (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) compared with interferon beta-1a in 1,313 patients with RMS between the ages of 18 and 55 years old. In this post-hoc analysis of 874 patients, treatment effect on serial brain volume, including thalamic volume and cortical grey matter, was evaluated by patient age (18 to 25, n=146; 26 to 34, n=265; 35 and older, n=463) at baseline, 12 months and 24 months.

    Patients in the 18 to 25 age group tended to have greater brain volume at baseline but more active disease as measured by gadolinium-enhancing MRI lesions. There was also a trend for this age group to experience greater whole brain volume loss at both 12 and 24 months compared with the older groups.

    Patients across all age groups treated with ozanimod lost less cortical grey matter volume than did those treated with interferon beta-1a over 24 months, including patients in the 18 to 25 age group.

    In the RADIANCE Part B trial, the most common adverse reactions (≥ 5 percent) that were higher with ozanimod than with interferon beta-1a were upper respiratory tract infections, urinary tract infections, increases of alanine aminotransferase and increases of gamma-glutamyl transferase.

    “Since loss of brain volume can be associated with disease progression, there is a need for early diagnosis and treatment in multiple sclerosis,” said Alise Reicin, M.D., President, Global Clinical Development for Celgene. “This analysis adds to growing evidence supporting the potential use of ozanimod to treat adults with relapsing multiple sclerosis, including the youngest patients studied, who also showed the most rapid loss in brain volume in this study.”

    Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). Ozanimod is an investigational compound that is not approved for any use in any country.

    Celgene submitted a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency in March 2019 for ozanimod for the treatment of adults with RMS.

    About RADIANCE™ Part B

    RADIANCE Part B is a pivotal, Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trial evaluating the efficacy, safety and tolerability of two doses of oral ozanimod (0.92 mg and 0.46 mg, equivalent to 1 mg and 0.5 mg ozanimod HCI respectively) against weekly intramuscular interferon beta-1a (Avonex®) over a 24-month treatment period. The study included 1,313 people living with RMS across 150 sites in 21 countries.

    The primary endpoint of the trial was annualized relapse rates (ARR) over 24 months. The secondary MRI endpoints included the number of new or enlarging hyperintense T2-weighted brain MRI lesions over 24 months, number of gadolinium-enhanced brain MRI lesions at month 24 and percent change from baseline in whole brain volume at month 24. Cortical grey and thalamic volume changes were also prospectively assessed versus active comparator.

    An analysis of the time to onset of 3-month confirmed disability progression was pre-specified using pooled data from both the SUNBEAM and RADIANCE Part B Phase 3 trials.

    About Ozanimod

    Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). Ozanimod causes lymphocyte retention in lymphoid tissues. The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve the reduction of lymphocyte migration into the central nervous system.

    Ozanimod is in development for immune-inflammatory indications including RMS, ulcerative colitis and Crohn's disease.

    About Multiple Sclerosis

    Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves. The myelin damage disrupts communication between the brain and the rest of the body. Ultimately, the nerves themselves may deteriorate — a process that's currently irreversible. Signs and symptoms vary widely, depending on the amount of damage and the nerves affected. Some people living with MS may lose the ability to walk independently, while others experience long periods of remission during which they develop no new symptoms. MS affects approximately 400,000 people in the U.S. and approximately 2.5 million people worldwide.

    RMS is characterized by clearly defined attacks of worsening neurologic function. These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods (remissions), during which symptoms improve partially or completely with no apparent progression of disease. RMS is the most common disease course at the time of diagnosis. Approximately 85 percent of patients are initially diagnosed with RMS, compared with 10-15 percent with progressive forms of the disease.

    About Celgene

    Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next‐generation solutions in protein homeostasis, immuno‐oncology, epigenetics, immunology and neuro‐inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

    Forward-Looking Statements

    This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission, including factors related to the proposed transaction between Bristol-Myers Squibb and Celgene, such as, but not limited to, the risks that: management’s time and attention is diverted on transaction related issues; disruption from the transaction make it more difficult to maintain business, contractual and operational relationships; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company could delay or prevent the proposed transaction; and Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel.

    Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.

    All trademarks are the property of their respective owners.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20190507005262/en/

    CONTACT:

    For inquiries:

    Investors:
    Nina Goworek
    Executive Director, Investor Relations
    908-673-9711

    Media:
    Catherine Cantone
    Senior Director, Corporate Communications
    908-897-4256

    分享到:
    第一金融网免责声明:
    1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
    2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
    3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
    发表评论

    【发表评论】(网友评论内容只代表网友观点,与本站立场无关?。?/td>
     姓 名:
     评 分: 1分 2分 3分 4分 5分
     评论内容:
    验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  行业人士:中美贸易争端是造成金属价格剧烈波动
     联合国报告:近百万物种面临灭绝 海洋塑料污染“
    [银行]  渤海银行去年贷款减值损失72亿元 逾期贷款137亿
     中国一银行高管受贿¥4000万 豪车房产居多 曾经
    [股票]  A股市值一日蒸发3.58万亿 北上资金玩“回马枪”
     一天跌去3.5万亿!A股跌出多项纪录:1147股跌停
    [基金]  A股昨日大跌 部分私募逆市加仓
     A股“惊魂一日”:私募挥泪狠砍仓位 轻仓者欲入
    [保险]  5月1日起社保费率正式下调,对你有啥影响?六问
     800万保险代理人被骗子盯上 齐保网涉嫌诈骗被端
    [期货]  涨!跌!玉米价格“过山车” 存货怎么办?
     国内期市涨跌互现 原油收涨2.5%
    [股评]  谁在狂奔入???深交所刚刚发布权威数据:1000万
     自营盘动向浮出水面 券商 “抄底”医药股
    [港股]  中国移动:4G基站数达到241万个 超过电信、联通
     小米集团遭雷军套现45亿港元? 半年市值蒸发300
    [美股]  谷歌发布$399新Pixel手机进军中端市场 能分走多
     "没有教科书能预料到" 股神巴菲特股东大会前谈经
    [外汇]  人民币对美元汇率中间价报6.8526元 下调124个基
     截至2018年12月末 中国外汇储备规模为30727亿美
    [债券]  中国2月小幅增持美债42亿美元 持债规模持续3个月
     “中国大妈”爱上的这款新理财 为啥冷暖两重天?
    [黄金]  刘智辛:欧美货币持稳,黄金日线三连阳,原油多
     央行连续4个月耗资120亿元爆买黄金!全球都在买
    [理财]  民政部回应德云社演员众筹事件:将引导平台修订
     花650万美元进斯坦福当事人母亲发声:录取后才捐
    [信托]  信托业一批防风险新规将出台
     民生信托撤回对乐视控股及贾跃亭执行申请 已追回
    [房产]  发改委:放宽落户并非放松楼市调控
     海南暂停富力红树湾商品房销售 项目被曝破坏红树
    [汽车]  颜值即正义,这些车的内饰你觉得好看吗?
     吐血整理!自驾游必带的装备是这几样
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 电子游戏 All Rights Reserved 版权所有·电子游戏 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以电子游戏名义做股票推荐的行为均属违法!

    广告商的言论与行为均与电子游戏无关!股市有风险,投资需谨慎。

    合作邮箱:电子游戏 合作电话:18678839953 点击这里给我发消息

  • 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 四川破获一起盗用“老板”微信骗财务转账案 2019-03-29
  • 七一党课:严书翰教授谈重温“不忘初心” 2019-03-26
  • [大笑]山不在高,有仙则名,水不在深,有龙则灵,文不在多,逻辑通透则行! 2019-03-10
  • 青岛国际啤酒节7月开幕 青岛西海岸邀客把酒狂欢--旅游频道 2019-03-10
  • 上海时时乐号码走势 北京赛车开奖结果 篮球胜分差中大奖 排列5计算 3d开机号今天是彩宝网 四川时时彩app下载手机版下载手机版下载手机版 舟山飞鱼走势怎么看 okooo澳客网pk10 北京快乐8开奖视频 北京pk10靠谱刷水方案 顶呱刮新票2018 海南环岛赛彩票开奖查询 幸运武林中奖规则 河南22选5开奖结果 北京pk10正规平台平台 腾讯分分彩开奖漏洞